In a world where pharma companies spend billions on trials that take a decade to produce evidence, Verasci is betting everything on a radical idea: what if you could fuse clinical science with software engineering to generate evidence faster than ever? This isn't a platform for finding trials—it's an engine for creating them.

"They're not selling software. They're selling speed-to-evidence."

The absence of public traffic data is telling. Verasci isn't a consumer-facing platform—they're B2B2C, selling directly to pharma and biotech companies. Their '0 monthly visits' to verasci.com isn't a failure; it's a strategic choice. They're not chasing clicks. They're chasing contracts. The real traffic happens behind enterprise firewalls, where clinical operations teams evaluate their platform for multi-million dollar implementations.

• Deep scientific expertise fused with global scale—combining clinical knowledge with operational reach
• Broadest endpoint technology platform—claiming coverage across the entire evidence generation lifecycle
• 65-person team generating $13.1M—implying ~$200K revenue per employee, strong for a clinical tech company
• No public funding—likely bootstrapped or backed by strategic investors who don't need public visibility